Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Chris Boylan who wrote (9023)	3/9/1999 12:44:00 PM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

You said>>>>>I've been worried for the last 6 months that the study problem was that there was statistically insignificant spread in the death rates between the two groups.<<<< To me, once again, senseless rambling but perhaps a feeble way to shroud your agenda to spread false information? DUH, now why would DSMB say continue trial if your supposed scenario was true?

To: Chris Boylan who wrote (9023)	3/9/1999 5:05:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

" patients enrolled that are too healthy and instead of the supposedly "normal" 20% death rate in the control group" The trial is designed for two groups of patients and the acuity of the disease is according to the modified Glasgow score. This insures that the patients are 1. very sick (enrolled)2.gravely sick (enrolled)3.dying (not enrolled) 4. moderately sick (not enrolled) Both group 1 and 2 are further divided on placebo or bpi. It seems that they planned for total and subgroup analysis from day one. (which is appropriate). "You can not assume that Neuprex is producing a favorable result because the study is continuing." I agree, only that product is safe. But not that it is not working as you have mentioned. "the DSMB is a creation of XOMA designed to oversee" no, it is appointed by the FDA. "XOMA explicitly decided up front not to release any results on an interim." DSMB could stop trial at any time for good or bad results independent of xoma. But the designed of trial and aims are rightly not release (they could) and I agree here with you:financing, and I will add legal reasons (fear of lawsuits due to creation of hype) Even if your suspiciousness is right and one have low mortality across the range of patients it only speaks good of bpi. Of course, one will need more recruits. As long as the DSMB allows the trial to continue they are seeing good hope, remember they are also bias for good results, they are clinicians and they also want a product that works. cacaito